MITOMYCINS
Hepatocellular Carcinoma
Blokhin's Russian Cancer Research CentermixturePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
521 Active assets in the Hepatocellular Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Adefovir Bukwang Pharmaceutical | Phase 4 | BBB |
Huaier Granule Tongji Hospital | Phase 4 | BBB |
Theprubicin RWTH Aachen University | Phase 4 | BB |
nrt6003 Second Affiliated Hospital of Guangzhou Medical University | Phase 3 | BB |
Inno-206 VA Office of Research and Development | Phase 4 | BB |
View all 50 →
Same molecule, other indications
MITOMYCINS is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →